Patents by Inventor Danica Antonia Rankic

Danica Antonia Rankic has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HSD17B13 INHIBITORS AND/OR DEGRADERS
    Publication number: 20240150334
    Abstract: Described herein are compounds of Formula I, wherein the variables are defined herein, their use as HSD17B13 inhibitors and/or degraders, pharmaceutical compositions containing such compounds and their use to treat, for example, NAFLD and NASH.
    Type: Application
    Filed: October 6, 2023
    Publication date: May 9, 2024
    Applicant: Pfizer Inc.
    Inventors: Jan Antoinette Cusi Romero Adams, Bruce Michael Bechle, Jason Kenneth Dutra, Michelle Renee Garnsey, Xinjun Hou, Jisun Lee, Deane Milford Nason, II, Steven Victor O'Neil, Danica Antonia Rankic, Yang Wang, Ann Sorrentino Wright, Lei Zhang, Liying Zhang, David James Edmonds
  • Heteroarylphenoxy benzamide kappa opioid ligands
    Patent number: 10316021
    Abstract: The present invention provides compounds of Formula I: and pharmaceutically acceptable salts thereof wherein the variables R1, R2, R3, R4, R9, X, m and n are as defined herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating kappa opioid (?-opioid) associated disorders including, e.g., a neurological disorder, or psychiatric disorder such as a neurocognitive disorder, substance abuse disorder, depressive disorder, anxiety disorder, trauma and stressor related disorder and feeding and eating disorder.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: June 11, 2019
    Assignee: Pfizer Inc.
    Inventors: Natasha Mariam Kablaoui, Michael Eric Green, Justin Ian Montgomery, Michael Aaron Brodney, Patrick Robert Verhoest, Gregory Wayne Kauffman, Danica Antonia Rankic, Scot Richard Mente, Bruce Nelsen Rogers, Kapildev Kashmirilal Arora, Matthew Francis Dunn
  • HETEROARYLPHENOXY BENZAMIDE KAPPA OPIOID LIGANDS
    Publication number: 20180148432
    Abstract: The present invention provides compounds of Formula I: and pharmaceutically acceptable salts thereof wherein the variables R1, R2, R3, R4, R9, X, m and n are as defined herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating kappa opioid (?-opioid) associated disorders including, e.g., a neurological disorder, or psychiatric disorder such as a neurocognitive disorder, substance abuse disorder, depressive disorder, anxiety disorder, trauma and stressor related disorder and feeding and eating disorder.
    Type: Application
    Filed: November 22, 2017
    Publication date: May 31, 2018
    Applicant: Pfizer Inc.
    Inventors: Natasha Mariam Kablaoui, Michael Eric Green, Justin Ian Montgomery, Michael Aaron Brodney, Patrick Robert Verhoest, Gregory Wayne Kauffman, Danica Antonia Rankic, Scot Richard Mente, Bruce Nelsen Rogers, Kapildev Kashmirilal Arora, Matthew Francis Dunn
  • SUBSTITUTED PYRIDO[1,2-a]PYRAZINES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
    Publication number: 20170166566
    Abstract: Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I wherein X, R1, R2a, R2b, R4a, R4b,R5a, R5b, R6, R7, y and z are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    Type: Application
    Filed: February 24, 2017
    Publication date: June 15, 2017
    Inventors: Martin Youngjin Pettersson, Christopher William am Ende, John Michael Humphrey, Douglas Scott Johnson, Gregory Wayne Kauffman, Danica Antonia Rankic, Antonia Friederike Stepan, Patrick Robert Verhoest
  • NOVEL CHROMENE AND 1,1a,2,7b-TETRAHYDROCYCLOPROPA[C]CHROMENE PYRIDOPYRAZINEDIONES
    Publication number: 20150274721
    Abstract: Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I wherein X, R1, R2a, R2b, R4a, R4b, R5a, R5b, R6, R7, y and z are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    Type: Application
    Filed: March 27, 2015
    Publication date: October 1, 2015
    Inventors: Martin Youngjin Pettersson, Christopher William am Ende, John Michael Humphrey, Douglas Scott Johnson, Gregory Wayne Kauffman, Danica Antonia Rankic, Antonia Friederike Stepan, Patrick Robert Verhoest